The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Martin Bidlingmaier is Head of the Endocrine Laboratory and leads the Neuroendocrine Research Group at the Department of Internal Medicine, Ludwig-Maximilians University, Munich, Germany. Dr Bidlingmaier received his medical degree from the Ludwig-Maximilians University in 1993. Since then, he has trained in Internal Medicine, Endocrinology, Clinical Chemistry, and Microbiology.
His research interests include the development and validation of laboratory methods for investigating pituitary and adrenal hormones, the endocrine aspects of doping in sports, as well as the physiology, pathophysiology and biomarkers of growth hormone action.
Dr Bidlingmaier is a member of various national and international associations, such as the German, the European and the US Endocrine Societies. He is Secretary of the international Growth Hormone Research Society, and Chair of the Sections for Endocrine Laboratory Diagnostics for both the German Endocrine Society and the German Society for Clinical Chemistry and Laboratory Medicine. Dr Bidlingmaier is a scientific advisor of the German Reference Institute for Bioanalytics. Between 2011–2019 he served as a member of the World Anti-doping Agencies (WADA) Prohibited List Expert Group and he is a current member of WADA’s Endocrine Working Group. He is also a member of the German National Anti-Doping Agencies Commission for the Doping Control System.
Dr Bidlingmaier has authored more than 330 articles in peer-reviewed journals and is currently an Editor of Pituitary. He has served on the Editorial Board of scientific journals including, The Journal of Clinical Endocrinology and Metabolism, Growth Hormone & IGF Research and Molecular Metabolism.
University of Gothenburg, Gothenburg, Sweden.
Gudmundur Johannsson is a Professor of Endocrinology and Deputy Director of the Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, and a Senior Consultant at the Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg, Sweden.
He received his medical degree from the University of Iceland, Reykjavik, Iceland, and trained in internal medicine and clinical endocrinology at Sahlgrenska University Hospital.
In 1997, he completed his thesis on growth hormone replacement in adults with hypopituitarism. He became a Senior Lecturer at Sahlgrenska Academy in 2003 and then Professor of Endocrinology in 2010. He was Head of the Department of Endocrinology at Sahlgrenska University Hospital between 2000–2011 and Co-Director, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy between 2015–2018. He was a Visiting Professor at the University of New South Wales, Sydney between 2001–2003.
Professor Johansson’s major research interests include pituitary diseases and adrenal insufficiency. He is a board member and former president of the Growth Hormone Research Society and serves on the Editorial Board of various scientific journals, such as Pituitary, Journal of Endocrine Society, Journal of Endocrinological Investigation, Reviews in Endocrinology and Metabolism Disorders, and Best Practice & Research Clinical Endocrinology and Metabolism. Professor Johannsson has more than 300 publications in peer-reviewed journals.
Nara Medical University, Nara, Japan.
Yutaka Takahashi is a professor at the Division of Diabetes and Endocrinology, Nara Medical University, Japan. He received his PhD in 1996 at Kobe University.
His research interests include case-oriented or disease-oriented research, especially in the field of pituitary and adrenal research. Within his work, he has established the novel clinical entity, “paraneoplastic autoimmune hypophysitis”, which includes anti-PIT-1 hypophysitis, a type of isolated adrenocorticotropic hormone (ACTH) deficiency and immune checkpoint inhibitor-related hypophysitis.
He is a member of the Board of Directors of the Pituitary Society, the Japan Endocrine Society, and the Japan Neuroendocrine Society, and is also a Council member of the Japanese Society for Hypothalamic and Pituitary Disease.
Beverly MK Biller
Harvard Medical School, Massachusetts, USA.
Beverly MK Biller, MD, is a Professor of Medicine at Harvard Medical School (HMS) and a faculty member in the Neuroendocrine & Pituitary Tumor Clinical Center at Massachusetts General Hospital (MGH) in Boston, Massachusetts, USA.
She is Program Director of the Clinical Fellowship in Adult Endocrinology and Metabolism at MGH. Dr Biller also directs the annual HMS & MGH Continuing Medical Education course "Clinical Endocrinology", which welcomes endocrinologists from around the world to Boston (now virtually) every Spring.
Major research interests include the diagnosis and treatment of Cushing’s disease, acromegaly, prolactinomas, and pituitary hormone deficiencies in adults. Dr Biller has published original research in many peer-reviewed journals and has co-authored clinical guidelines regarding growth hormone deficiency, Cushing’s disease, acromegaly, and pituitary adenomas in pregnancy for the American Association of Clinical Endocrinologists, the Endocrine Society, the Pituitary Society, and the European Society of Endocrinology, respectively.